The domestic biotech and pharmaceutical sectors are experiencing overall strength, riding a favorable tailwind in the market. Broad buying interest has flowed in from large-cap to mid- and small-cap stocks, significantly improving investment sentiment across the industry.

During the morning session on the 29th, Samchundang Pharmaceutical and Alteogen led the gains with sharp advances. Samchundang Pharmaceutical recorded an increase of over 10%, while Alteogen also posted a rise nearing double digits, demonstrating its presence as a major large-cap biotech stock.

Celltrion maintained its upward trajectory backed by its competitiveness in the biosimilar business and steady buying interest, while Green Cross also rose in tandem, benefiting from improved investor sentiment. Chong Kun Dang and Boryung joined the rally in pharmaceutical stocks, further buoying the sector's mood.

The standout stocks of the day were Hanmi Pharmaceutical and Hanall Biopharma. Hanmi Pharmaceutical exhibited the most pronounced strength among major pharma stocks with a surge exceeding 14%, and Hanall Biopharma also drew strong investor interest with a jump of over 17%.

In addition, a diverse range of biotech and pharmaceutical companies, including Daewoong Pharmaceutical, Bionex, Prestige Biopharma, Prestige Biologics, ISU Abxis, Dong-A ST, Aprogen, and Aprogen Biologics, all trended higher simultaneously, spreading warmth across the entire sector.

The market analysis suggests that bargain-hunting buying is flowing in earnest into the biotech sector, which recently underwent a correction. Assessments indicate that a combination of factors — including the expansion of the biosimilar market, expectations for new drug development, and the possibility of global technology transfers — are firmly supporting investor sentiment.

However, experts advised that because biotech stocks are highly volatile depending on clinical trial results, technology transfers, and regulatory approvals, investors should carefully examine individual companies' financial performance and business progress before investing.

[This article was written with the assistance of AI. Based on publicly available data, this article utilized AI for part of the writing process and was completed after final editing and fact-checking. This article is not intended to solicit investment, and the final judgment and responsibility for investments lie with the investor.]